Biochem/physiol Actions
LY2090314 can decrease the development of human MYCN amplified and non-amplified neuroblastoma (NB) cell lines in vitro. It has the ability to prevent the multiplication, colony formation and cell confluency of neuroblastoma.
LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3) currently in clinical trials for cancer therapy. LY2090314 has IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
- UPC:
- 41116127
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- SML1438-5MG
- Product Size:
- 5/MG
- CAS:
- 603288-22-8
